Jeremy Bender - 07 Jul 2026 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Reporting relationship: Director
Issuer ticker: AURA
Reported as of: 07 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jul 2026, 16:11:50 UTC
Prior SEC filing: 23 Apr 2026
Next SEC filing: 29 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Conor Kilroy, as Attorney-in-Fact

Key filing fact

Jeremy Bender filed Form 4 for Aura Biosciences, Inc. (AURA) on 08 Jul 2026.

Key facts

This page summarizes Jeremy Bender's Form 4 filing for Aura Biosciences, Inc. (AURA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Jul 2026, 16:11.

Change

Previous filing in this sequence was filed on 23 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001863107 Primary reporting owner

Bender Jeremy

Relationship: Director
Address: C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON
Signature: /s/ Conor Kilroy, as Attorney-in-Fact
Signature date: 08 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AURA transaction

Common Stock

Award

Transaction value
Shares: +30,000
Change %
Price: $0.000000^*
Shares after: 30,000
Date: 07 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AURA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +60,000
Change %
Price: $0.000000^*
Shares after: 60,000
Date: 07 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $7.03
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in three substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

Footnote F2

The shares underlying this option vest in three substantially equal annual installments beginning on July 7, 2027, subject to the Reporting Person's continued service as of each such vesting date.